Last reviewed · How we verify
NCT04606329
To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)
Phase 3 trial testing LuminoMark inj.(Conc. for fluorescence) in Breast Diseases in 109 participants. Completed in 28 January 2021.
28 January 2021
Quick facts
| Lead sponsor | Hanlim Pharm. Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 109 |
| Start date | 20 July 2020 |
| Primary completion | 28 January 2021 |
| Estimated completion | 28 January 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- LuminoMark inj.(Conc. for fluorescence) — full drug profile →
- Charcotrace Inj. — full drug profile →
Conditions studied
- Breast Diseases — all drugs for Breast Diseases →
Sponsor
Hanlim Pharm. Co., Ltd. — full company profile →
Who can join
Adults 19 to 80, any sex, with Breast Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, Randomized, Open-label, Parallel, Phase 3 Clinical Trial in 8 weeks for screening, once Investigational product injection, Follow up visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04606329
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Diseases
Currently open trials in the same condition.
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07038369 — A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · Phase 1 · active not recruiting
- NCT07010939 — A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients · recruiting
- NCT06780176 — A Study of Breast Cancer Risk Factors and Outcomes of People in Florida · recruiting
Other Hanlim Pharm. Co., Ltd. trials
Trials by the same sponsor.
- NCT06475872 — Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuva · Phase 1 · completed
- NCT06642987 — Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adu · Phase 1 · completed
- NCT06246331 — Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection · unknown
- NCT06130124 — S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement · unknown
- NCT05358080 — Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04606329 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hanlim Pharm. Co., Ltd.
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04606329.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing